Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a Midwest Pediatric Nephrology Consortium study.

Selewski DT, Massengill SF, Troost JP, Wickman L, Messer KL, Herreshoff E, Bowers C, Ferris ME, Mahan JD, Greenbaum LA, MacHardy J, Kapur G, Chand DH, Goebel J, Barletta GM, Geary D, Kershaw DB, Pan CG, Gbadegesin R, Hidalgo G, Lane JC, Leiser JD, Song PX, Thissen D, Liu Y, Gross HE, DeWalt DA, Gipson DS.

Pediatr Nephrol. 2014 Jun 9. [Epub ahead of print]

PMID:
24908324
[PubMed - as supplied by publisher]
2.

Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study.

Gipson DS, Selewski DT, Massengill SF, Wickman L, Messer KL, Herreshoff E, Bowers C, Ferris ME, Mahan JD, Greenbaum LA, MacHardy J, Kapur G, Chand DH, Goebel J, Barletta GM, Geary D, Kershaw DB, Pan CG, Gbadegesin R, Hidalgo G, Lane JC, Leiser JD, Plattner BW, Song PX, Thissen D, Liu Y, Gross HE, DeWalt DA.

Health Qual Life Outcomes. 2013 Mar 4;11:30. doi: 10.1186/1477-7525-11-30.

PMID:
23510630
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Promising insights into the health related quality of life for children with severe obesity.

Selewski DT, Collier DN, MacHardy J, Gross HE, Pickens EM, Cooper AW, Bullock S, Earls MF, Pratt KJ, Scanlon K, McNeill JD, Messer KL, Lu Y, Thissen D, DeWalt DA, Gipson DS.

Health Qual Life Outcomes. 2013 Mar 1;11:29. doi: 10.1186/1477-7525-11-29.

PMID:
23452863
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

Peyser A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H.

BMC Nephrol. 2010 Jan 29;11:2. doi: 10.1186/1471-2369-11-2.

PMID:
20113498
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H.

Am J Kidney Dis. 2010 Jan;55(1):50-60. doi: 10.1053/j.ajkd.2009.08.019. Epub 2009 Nov 22.

PMID:
19932542
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk